How DIR Fees Affect Pharmacy Valuation
Understanding how DIR fees affect pharmacy valuation is essential for anyone buying or selling an independent pharmacy. Direct and indirect remuneration (DIR) fees and similar post-sale adjustments can reduce what a pharmacy actually keeps from its prescriptions, and they can make reported earnings look different from the cash flow a buyer will really inherit.
Because value and loan size are generally based on normalized earnings, how these fees are measured and adjusted can move the price of a pharmacy significantly. This article explains the key issues. Payer arrangements vary and continue to change, and nothing here is legal, tax, accounting, billing or compliance advice. Buyers and sellers should work with accountants, valuation professionals and qualified billing advisors.
What DIR Fees Are, in Brief
DIR fees have historically referred to price concessions and other adjustments that reduce a pharmacy’s reimbursement for prescriptions, particularly in Medicare Part D. In the past, many of these fees were assessed after the point of sale, sometimes long after the prescription was filled, based on performance measures or other contract terms.
Rule changes for Medicare Part D have shifted many pharmacy price concessions to the point of sale. Even so, historical financial statements may reflect years of retroactive fees, and some payer arrangements may still involve after-the-fact adjustments. That history and the ongoing terms both matter for valuation.
Why Reported Earnings Can Be Misleading
When fees are assessed after the sale, they can show up in the financial statements in a different period from the prescriptions that generated them. This creates several potential distortions:
- Timing mismatch: a period’s revenue may look strong while the fees tied to it appear later
- Lumpy expenses: large reconciliations can make one period look unusually weak
- Inconsistent accounting: some pharmacies record fees as reductions to revenue, others as expenses, and some estimate accruals while others do not
- Changing rules: a shift to point-of-sale concessions can change the pattern of margins from one period to the next
A buyer looking only at headline profit may over- or under-estimate the pharmacy’s true earning power.
Consider two pharmacies with similar reported profit. One recorded fees as they were assessed and accrued expected reconciliations; the other recorded nothing until payments were taken back. On paper they look alike, but the second may carry hidden obligations or a margin trend that is weaker than it appears. Normalizing the numbers helps reveal the difference.
How DIR Fees Affect Pharmacy Valuation in Practice
Valuations of independent pharmacies generally start from normalized earnings or cash flow. DIR fees can influence that figure in several ways:
- Normalizing past fees: valuators may reallocate fees to the periods that generated them to show a truer trend
- Adjusting for rule changes: historical margins may be restated to reflect how current reimbursement is calculated
- Assessing payer mix: a pharmacy heavily weighted toward Medicare Part D or certain networks may face different margin pressure than one with a broader mix
- Weighing performance programs: if any reimbursement still depends on quality or performance measures, the pharmacy’s track record matters
- Considering risk: uncertainty about future fee structures may lead buyers to apply a more conservative view of earnings
Our article on how a pharmacy practice is valued explains the broader framework these adjustments fit into.
How Lenders View DIR Fees
Lenders financing a pharmacy acquisition typically size the loan based on cash flow available to service debt. If DIR fees or similar adjustments reduce that cash flow, they can also reduce how much a buyer may be able to borrow. Lenders may:
- Request remittance and reconciliation detail along with tax returns
- Adjust earnings for fees that were not reflected in the periods reviewed
- Ask how current reimbursement compares with historical margins
- Consider whether working capital is sufficient to absorb ongoing adjustments
Our article on how much you can borrow to buy a pharmacy explains how cash flow drives loan size. Every loan is subject to approval, and nothing here is a commitment to lend.
What Buyers Should Request
During diligence, buyers may want:
- Remittance advice and reconciliation reports covering several years
- A schedule of fees and clawbacks by payer and by period
- An explanation of how fees were recorded in the financial statements
- Any performance program scorecards or reports
- Information on outstanding or expected reconciliations at closing
These items fit naturally into a broader pharmacy due diligence checklist. The purchase agreement should also address who bears fees and adjustments tied to prescriptions filled before closing.
What Sellers Can Do
Sellers can help support value by organizing fee history, recording fees consistently, explaining unusual periods and working with their accountant to present normalized earnings clearly. Sellers planning an exit may also benefit from advisory and valuation consulting before going to market.
Other Timing Issues to Consider
DIR fees are not the only factor that can separate reported profit from actual cash. Negotiated Medicare drug prices can also create a refund float for pharmacies, as discussed in our article on maximum fair price and pharmacy cash flow. Buyers should consider these timing issues together.
Final Thoughts
Knowing how DIR fees affect pharmacy valuation helps buyers avoid overpaying and helps sellers present their business credibly. Because fees can be recorded inconsistently and rules continue to evolve, normalized earnings, clear documentation and careful diligence are central to agreeing on price and securing financing.
US Medical Funding helps pharmacists and investors finance independent pharmacy acquisitions. Learn more about our pharmacy acquisition financing and our full range of pharmacy financing options.
